Intelligence / Healthtech / New Clinical Trials / Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
26 Oct 2026: Trial registered · A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 26 Oct 2026
- Title
- A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07896005
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Suzhou Suncadia Biopharmaceuticals Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Suzhou Suncadia Biopharmaceuticals Co., Ltd. in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.